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Abstract  
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast 
tumours. Precision medicine approaches that exploit this characteristic are not 
available. Using perturbation screens in breast tumour cells with CRISPR-Cas9 
engineered CDH1 mutations, we identified synthetic lethality between E-cadherin 
deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic 
screens in molecularly diverse breast tumour cell lines established that the E-
cadherin/ROS1 synthetic lethality was not only robust in the face of considerable 
molecular heterogeneity but was also elicited with clinical ROS1 inhibitors including 
foretinib and crizotinib. ROS1 inhibitors induced mitotic abnormalities and 
multinucleation in E-cadherin defective cells, phenotypes associated with a defect in 
cytokinesis and aberrant p120-catenin phosphorylation and localisation. In 
vivo, ROS1 inhibitors produced profound anti-tumour effects in multiple models of E-
cadherin defective breast cancer. This data therefore provides the pre-clinical 
rationale for assessing ROS1 inhibitors such as the licensed drug crizotinib in 
appropriately stratified patients. 
 
Statement of significance 
E-cadherin defects are common in breast cancer but are currently not targeted with a 
precision medicine approach. Our pre-clinical data indicate that licensed ROS1 
inhibitors, including crizotinib, should be repurposed to target E-cadherin defective 
breast cancers, thus providing the rationale for the assessment of these agents in 
molecularly–stratified phase 2 clinical trials. 
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Introduction 
E-cadherin defects are frequently found in breast cancer (>13 %) and gastric cancer 
(>14%) and are particularly prevalent in lobular breast cancers, which account for 
15% of all mammary carcinomas (1). CDH1 encodes a calcium-dependent plasma 
membrane-bound cell-cell adhesion glycoprotein (2). In epithelial cells, E-cadherin 
forms homotypic adhesive complexes, known as adherens junctions that control cell-
cell contact, the contractility of cells and ultimately the integrity of epithelial cell layers 
(3). Whilst the extracellular domain of E-cadherin interacts with E-cadherin molecules 
on adjacent cells, the intracellular domain interacts with, and controls, a number of 
proteins including p120-catenin (p120), α-catenin, γ-catenin, β-catenin, receptor 
tyrosine kinases, and a series of plasma membrane-associated receptors and 
cytoskeletal proteins (2). Loss of E-cadherin function causes a wide variety of 
phenotypes ranging from defects in cell migration and the orientation of the mitotic 
spindle, as well as dysregulation of cell-cell adhesion and anoikis resistance 
(reviewed in (3)). 
 
In lobular breast cancer, loss of E-cadherin expression occurs early on in the 
tumourigenic process and is seen in up to 90% of cases often co-occurring with 
mutations in the PI3-kinase coding gene, PIK3CA (4). Lobular breast cancers tend 
to be estrogen receptor (ER) and progesterone receptor (PR) positive, ERBB2 
amplification-negative, have a low Ki67 index and a luminal-A intrinsic subtype 
(1,5-7). Whilst these biomarkers might predict a favorable response to adjuvant 
endocrine therapy, retrospective analyses of two recent clinical trials (BIG 1-98 
and ABCSG-8) suggests that a subset of invasive lobular breast cancer (ILC) 
patients have poorer responses to endocrine therapy when compared to those with 
invasive ductal carcinomas (IDCs) that display similar biomarkers (8,9). 
Furthermore, pathological complete response rates after neoadjuvant 
chemotherapy are low in ILC (10,11), suggesting that additional approaches are 
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required to target this disease. In other breast cancer subtypes, E-cadherin 
expression might also influence patient outcome. For example in triple negative 
breast cancer, the prognosis of patients with E-cadherin-negative tumours is 
significantly worse than those with E-cadherin-positive disease (12,13).  
 
At present, it is not clear whether actionable or pharmacologically tractable E-
cadherin synthetic lethal effects can be identified that are likely to work clinically. 
Such clinically actionable synthetic lethal effects might be expected to be relatively 
resilient to additional molecular changes and operate in the face of a high-degree of 
molecular diversity that exits in cancer (i.e. hard synthetic lethal effects (14)). In the 
data presented below, we illustrate that the combined use of multiple, distinct, in 
vitro, ex vivo and in vivo model systems and the exploitation of different functional 
profiling modalities (genetic and chemical screens) can be used to identify robust and 
actionable E-cadherin synthetic lethal interactions. The most notable synthetic 
lethality we identified in this way was between E-cadherin and the ROS1 receptor 
tyrosine kinase, an effect that is clinically actionable using ROS1 inhibitors such as 
crizotinib or foretinib. 
 
Results 
Integrated genetic and small molecule screens identify a ROS1/E-cadherin 
synthetic lethal effect  
To identify candidate therapeutic targets for breast cancers with loss of E-cadherin, 
we used CRISPR-Cas9 mutagenesis in MCF7 breast tumour cells (ERα-positive, 
luminal A, PIK3CA mutant; described hereafter as MCF7Parental cells) to generate 
daughter clones, MCF7A02, MCF7B04 and MCF7B05, with frameshift mutations in CDH1 
and loss of E-cadherin expression (Fig. 1A and B; Supplementary Fig. S1). 
Compared to MCF7Parental cells, E-cadherin defective cells displayed a rounded 
morphology also seen in breast tumour cells harbouring naturally occurring E-
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cadherin mutations (Fig. 1C). We used MCF7A02 and MCF7Parental cells in two parallel 
functional screens to identify E-cadherin synthetic lethal effects: (i) a drug sensitivity 
screen where we assessed the relative sensitivity of cells to an in–house curated 
library of 80 small-molecule inhibitors that are either in clinical use for the treatment 
of cancer or in late-stage clinical development (Fig. 1D; Supplementary Table S1 and 
S2); and (ii) a parallel siRNA sensitivity screen, using siRNA SMARTpools (four 
different siRNAs targeting a single gene in each well) targeting >1000 cell cycle 
control genes, kinase-coding genes or DNA repair related genes (see methods, Fig. 
1E; Supplementary Table S3). The drug sensitivity screens identified a series of 
candidate E-cadherin synthetic lethal drugs, including PF-03758309 (a PAK 
inhibitor), PF-03814735 (an Aurora kinase inhibitor), PI3K/mTOR inhibitors (BEZ-
235, PF-04691502 and Everolimus), the ROS1/MET/ALK inhibitors (15) crizotinib 
(PF02341066, Pfizer) and foretinib (GSK1363089, GSK) (Fig. 1D; Supplementary 
Table S1 and S2). In order to identify E-cadherin synthetic lethal effects from our 
MCF7 isogenic cell line siRNA screen, we calculated the difference in siRNA Z 
scores between E-cadherin defective and E-cadherin proficient cells and identified 
104 E-cadherin synthetic lethal effects (p < 0.05, Fig. 1E; Supplementary Table S3). 
Gene ontology analysis of this 104 gene list using EnrichR (16) highlighted gene sets 
associated with myosin light chain kinase activity (Supplementary Table S4, adjusted 
p-value = 8.52 x 10-9, PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3, PIM1, 
CLK3, RPS6KA2, SBK1, STK38L, TGFBR1 and MYLK2), gene sets related to GTP-
dependent protein kinase activity (Supplementary Table S4, adjusted p-value = 1.35 
x 10-8, PLK3, AAK1, HUNK, CSNK1A1, NEK4, PAK4, CPNE3 PIM1, CLK3, 
RPS6KA2, SBK1, STK38L, TGFBR1), and a set of candidate synthetic lethal genes 
associated with Rho-dependent protein serine/threonine kinase activity 
(Supplementary Table S4, adjusted p-value = 1.35 x 10-8, PLK3, AAK1, HUNK, 
CSNK1A1, NEK4, PAK4, CPNE3, PIM1, CLK3, RPS6KA2, SBK1, STK38L, 
TGFBR1). Other gene sets identified in this analysis included genes associated with 
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RNA polymerase II carboxy-terminal domain kinase activity (Supplementary Table 
S4, adjusted p-value = 8.52E-09), protein serine/threonine kinase activity 
(Supplementary Table S4, adjusted p-value = 8.52 x 10-9) and calmodulin-dependent 
protein kinase activity (Supplementary Table S4, adjusted p-value = 8.85 x 10-9). 
 
Amongst the most significant hits in the siRNA screen was ROS1 (ROS Proto-
Oncogene 1, Receptor Tyrosine Kinase, Fig. 1E; Supplementary Table S3). We 
selected ROS1 for further study as: (i) the synthetic lethality observed with ROS1 
siRNA was statistically significant; and (ii) the parallel small molecule inhibitor screen 
identified ROS1 inhibitors (foretinib, crizotinib) as candidate synthetic lethal drugs, 
suggesting that the ROS1 effect might be clinically tractable. The siRNA screen did 
not identify other targets of crizotinib or foretinib (e.g. KDR, MET, ALK and AXL) as 
being candidate E-cadherin synthetic lethal effects (Supplementary Fig. S2). We also 
noted that in both MCF7 and MCF10A isogenic systems, loss of E-cadherin 
expression caused upregulation of ROS1 protein but did not elicit changes in either 
MET or ALK expression (Fig. 1F,G; Supplementary Fig. S3), suggesting that 
enhanced ROS1 expression could represent a homeostatic response to E-cadherin 
loss; re-expression of E-cadherin in E-cadherin defective MCF7A02 cells reversed this 
ROS1 induction (Fig. 1H), suggesting causality.  
 
In validation experiments, we found that each of the four individual ROS1 siRNAs 
from the ROS1 SMARTpool caused silencing of ROS1 and preferentially inhibited the 
E-cadherin deficient MCF7A02 clone and also an E-cadherin defective MCF10A 
CDH1–/– non-tumour cell line (Fig. 2A-C). Two further E-cadherin defective clones 
derived by MCF7 CRISPR-Cas9 targeting, MCF7B04 and MCF7B05, were also 
significantly more sensitive to either foretinib or crizotinib than the parental cells (Fig. 
2D; Supplementary Fig. S1), suggesting these effects were not private to MCF7A02. 
Restoring E-cadherin expression in MCF7A02 using a Flag-epitope tagged E-cadherin 
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cDNA expression construct reduced foretinib sensitivity as well as sensitivity to an 
additional ROS1/MET/ALK inhibitor, TAE673 (Fig. 2E and F), confirming that E-
cadherin influences the response to these agents. By assessing the effects of 
additional ROS1/MET/ALK inhibitors on E-cadherin isogenic cells, we found that 
foretinib and crizotinib gave the greatest difference in drug sensitivity between E-
cadherin wild type and defective cells (Fig. 2G), warranting their further investigation. 
The sensitivity of E-cadherin defective cells to foretinib was similar to that observed 
in HCC78 cells (Fig. 2H and I), which harbour a SLC34A2-ROS1 gene fusion 
rearrangement rendering the cell line highly addicted to ROS1 kinase activity (15). 
We also found E-cadherin defective cells to be sensitive to a recently described 
ROS1 kinase inhibitor, PF-06463922 (17) (Fig. 2J). Finally, transfection of E-cadherin 
defective MCF7A02 cells with increasing amounts of ROS1 siRNA enhanced the cell 
inhibitory effects of foretinib (Fig. 2K). Conversely, expression of a crizotinib-
refractory p.G2032R mutant ROS1 fusion cDNA (18) caused crizotinib resistance in 
E-cadherin defective cells (Fig. 2L), suggesting that ROS1 could be a critical 
foretinib/crizotinib target in these cells. 
 
Many synthetic lethal effects are private to a small number of model systems and do 
not operate universally in the face of the molecular diversity found in breast and other 
cancers (14). To assess whether the synthetic lethal effect of ROS1 inhibition could 
apply more widely in breast cancer with E-cadherin loss, we interrogated recently 
described in-house siRNA “Achilles’ Heel” screen data describing the kinase 
dependencies in 34 breast tumour cell lines (19). We first determined the E-cadherin 
protein expression in each of these 34 models by western blotting, classifying cell 
lines as either “E-cadherin defective” (n=12) or “E-cadherin wild-type” (n=22), and 
used these classifications to identify siRNAs that selectively targeted the E-cadherin 
defective cohort of breast tumour cell lines (Fig. 3A and B). We found that the “E-
cadherin defective” or “E-cadherin wild-type” status defined by western blotting was 
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consistent with E-cadherin protein expression data determined by mass spectrometry 
(MS) (20), as well as E-cadherin mRNA expression and CDH1 mutation data (Fig. 3C 
and D; Supplementary Table S5). For example, each of the tumour cell line models 
with CDH1 truncating mutations or homozygous deletions lacked E-cadherin protein 
expression; similarly breast tumour cell lines with CDH1 promoter hypermethylation 
(1,21), also lacked full length E-cadherin protein (Fig. 3A). Using the siRNA Achilles’ 
Heel screen data (19) (Fig. 3B), we identified 31 siRNAs that selectively targeted the 
E-cadherin deficient cohort (p < 0.05, median permutation t-test), including ROS1 
(Fig. 3E; Supplementary Fig. S4A and B median permutation t-test p = 0.04; 
Supplementary Table S6). We also assessed whether MET or ALK siRNA selectively 
targeted E-cadherin defective breast tumour cells, but in an analysis of 34 breast 
tumour cell lines, classified according to E-cadherin status (Supplementary Table 
S5), did not identify a significant association (Supplementary Fig. S5).  
 
We also interrogated previously published siRNA Achilles’ Heel screen data 
describing the kinase dependencies in an additional 69 non-breast cancer derived 
tumour cell lines (19). After annotating these according to E-cadherin status, we also 
noted a ROS1/E-cadherin synthetic lethal effect, suggesting that this effect was not 
necessarily specific to breast tumour models (Supplementary Fig. S6A-C; 
Supplementary Table S7). Validation experiments confirmed the ROS1/E-cadherin 
synthetic lethality in the breast tumour cell line models (Supplementary Fig. S7A-E), 
suggesting that this effect was not isolated to isogenic models, but also operated in 
molecularly diverse models of breast cancer.  
 
We also used an orthogonal analytical approach, REVEALER (Repeated evaluation 
of variables conditional entropy and redundancy (22), to identify the molecular 
features found in breast tumour cell lines that were most associated with sensitivity to 
ROS1 siRNA. REVEALER uses a set of molecular features (e.g. the presence or 
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absence of mutations or other defects in key cancer driver genes or proteins) and 
target inhibition data (in this case sensitivity to ROS1 siRNA) from tumour cell line 
profiling experiments to identify multiple, often complimentary, molecular features 
that correlate with target inhibition, quantifying these effects as non-linear information 
correlation coefficients (ICs), between 1 (perfect correlation/features associated with 
resistance to target inhibition) and –1 (perfect negative correlation/features 
associated with sensitivity to target inhibition); REVEALER ICs <–0.1 or >0.1 are 
regarded as profound correlations (22). We carried out a REVEALER analysis using 
the ROS1 siRNA Z score data in the breast tumour cell lines as the measure of target 
inhibition and the mutational status of the 23 recurrently mutated cancer driver genes 
in the breast tumour cell line panel plus the E-cadherin protein classification 
described above as molecular features. Using this approach, we found E-cadherin 
protein deficiency to have a far greater correlation with ROS1 siRNA Z score (IC -0.5) 
than any of the other molecular features analysed (Fig. 3F), supporting the 
hypothesis that E-cadherin status is an important determinant of sensitivity to ROS1 
inhibition in breast cancer. We also assessed the sensitivity of the breast tumour cell 
line panel to foretinib or crizotinib and found that the E-cadherin defective models 
were more sensitive to both inhibitors (Fig. 3G and H; Supplementary Table S8). The 
median sensitivity to either foretinib or crizotinib in the E-cadherin defective cohort 
was also similar to that in the SLC34A2-ROS1 translocated HCC78 tumour cell line 
model (Fig. 3G and H). The responses to ROS1 inhibitors observed in the tumour cell 
line panel appeared to be independent of epithelial or mesenchymal status. For 
example, MCF10A cells do not undergo EMT upon loosing E-cadherin expression 
(23) but did exhibit both foretinib and crizotinib sensitivity (Fig. 2H-J). Similarly, 
SUM149, a mesenchymal breast tumour cell line which has wild type E-cadherin 
expression (24) was not sensitive to ROS1 inhibition, whereas E-cadherin defective, 
epithelial cells (e.g. SUM44, SKBR3) were (Supplementary Fig. S8). Furthermore, we 
did not find that expression of MET, ALK, pAKT, AKT, pERK or ERK correlated with 
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E-cadherin status, nor drug sensitivity (Supplementary Fig. S9), suggesting that 
these were unlikely to be determinants of the synthetic lethal effects we identified. As 
ROS1 fusion genes are well established biomarkers of ROS1 inhibitor sensitivity we 
also analysed paired-end RNA-sequencing data using Chimerascan in order to 
identify ROS1 fusion genes in our tumour cell line panel (25,26). Whilst Chimerascan 
identified the SLC34A2-ROS1 fusion event in HCC78 lung tumour cells (the positive 
control), ROS1 fusions were not identified in any of the breast tumour cell lines 
(Supplementary Table S9). In addition, ROS1 copy number or ROS1 variants, 
although rare in our tumour cell line panel, did not appear to correlate with 
crizotinib/foretinib sensitivity (Supplementary Table S9). We did note an increase in 
ROS1 expression and phospho-ROS1 levels in E-cadherin defective cells, similar to 
that seen in E-cadherin isogenic systems (Fig. 1F-H; Supplementary Fig. S10), 
suggesting that enhanced ROS1 expression could represent a homeostatic response 
to E-cadherin loss. Finally, we interrogated recently published data describing drug 
sensitivity effects in ex vivo cultured breast cancer explants (27) to identify drug 
sensitivity effects associated with loss of E-cadherin. When querying this data for 
drug sensitivity effects associated with CDH1 gene copy number loss, we found 
sensitivity to crizotinib (PF-02341066 (27)) to be the most significant effect (Fig. 3I, p 
value 0.00127). The mean area under the curve (AUC) for crizotinib was 0.0713 in 
explants with CDH1 copy number loss (n = 5) and 0.138 in explants without CDH1 
copy number loss (n = 12; False Discovery Rate (FDR) 0.214).  
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ROS1 inhibitors elicit synthetic lethality in endocrine resistant, E-cadherin 
defective, breast tumour cells and in models of E-cadherin defective gastric 
cancer 
Given the central role of endocrine therapy in the treatment of ER+ve breast cancers 
and the frequency at which endocrine resistance develops, especially in the 
advanced disease setting (28), we assessed whether E-cadherin siRNA caused 
foretinib or crizotinib, sensitivity in previously-validated, endocrine therapy resistant, 
MCF7 LTED cells (29).  We found that E-cadherin siRNA caused both foretinib and 
crizotinib sensitivity in MCF7 LTED cells (p < 0.0001, ANOVA, Fig. 4A-E) as it did in 
endocrine sensitive MCF7 cells (Fig. 2G), suggesting that the E-cadherin 
foretinib/crizotinib synthetic lethal effects were somewhat independent of endocrine 
therapy sensitivity. We also found that ER+ve, de novo endocrine resistant and E-
cadherin defective MDAMB134VI tumour cells, which were derived from a case of 
invasive lobular carcinoma (30), were sensitive to ROS1 inhibitors in both in vitro 
(Supplementary Fig. S11A) and in vivo experiments (Supplementary Fig. S11B-D), 
suggesting that ROS1 inhibition could also target E-cadherin defective breast tumour 
cells in this particular setting. 
 
We next assessed whether crizotinib or foretinib sensitivity extended to models of E-
cadherin defective diffuse gastric cancer, given the elevated frequency of E-cadherin 
defects in this cancer subtype. We found that either crizotinib or foretinib selectively 
targeted E-cadherin defective gastric tumour cell lines (Supplementary Fig. S12A and 
B). The effects of crizotinib in additional gastric tumour cell lines have also been 
recently assessed (27,31). We reanalyzed this data and found that those tumour 
cells lines with reduced E-cadherin expression (defined by CDH1 mRNA levels) were 
more sensitive to crizotinib than those with higher E-cadherin expression 
(Supplementary Fig. S12C).  
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ROS1 inhibition exacerbates p120 catenin, cleavage furrow and cytokinesis 
defects in E-cadherin defective cells 
In investigating the cellular phenotypes associated with these E-cadherin selective 
effects, we found that exposure of E-cadherin defective cells to foretinib caused an 
increase in the proportion of cells with >4N DNA content (Fig. 5A and B), an increase 
in the frequency of cells with abnormal mitoses, particularly cells with multiple nuclei 
(Fig. 5C-F), an increase in expression of the G2/M DNA damage biomarker p21 (Fig. 
5G) and an increase in cellular apoptosis as assessed by PARP cleavage and 
caspase 3/7 activity (Fig. 5H-L; Supplementary Fig. S13). These phenotypes were 
reminiscent of those seen in Rhabdomyosarcoma tumour cells exposed to crizotinib 
(32) and Chronic Myeloid Leukemia (CML) tumour cell lines, where foretinib elicits 
phenotypes associated with mitotic catastrophe (MC) including multinucleated giant 
cells, increased DNA content and apoptotic cell death (33). 
To assess what might cause such multinuclear phenotypes, we visualised cells 
exposed to crizotinib or foretinib using live cell microscopy. We found that in both E-
cadherin wild type and defective cells, either foretinib or crizotinib extended the time 
cells spent in mitosis (Supplementary Fig. S14A and B). This extended mitosis had 
dichotomous effects, depending upon the status of E-cadherin. In E-cadherin wild 
type cells, exposure to a ROS1 inhibitor still resulted in the formation of two 
mononuclear daughter cells (Fig. 6A). In contrast, when exposed to a ROS1 inhibitor, 
E-cadherin defective cells initiated cytokinesis but failed to complete invagination of 
the cell membrane at the cleavage furrow, resulting in the formation of multinuclear 
cells (Fig. 6A). We noted that cytokinesis in E-cadherin defective cells exposed to 
foretinib or crizotinib was characterized by prolonged membrane oscillation, starting 
at the onset of anaphase, cleavage furrow regression resulting in multinucleated 
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cells, and also the formation of cells with lagging chromosomes (Fig. 6A; 
Supplementary Fig. S15; Supplementary Video S1-S5). 
Cytokinesis failure and a multinuclear phenotype have previously been associated 
with defective p120-catenin activity (p120) (34,35). Actomyosin contractility at the 
ingression and cleavage furrow during anaphase and telophase is controlled by 
p120, which mediates these effects via binding to the centralspindlin component 
MKLP1 and the GTPase RhoA (35). p120 catenin also normally interacts with E-
cadherin at the cell membrane where it is tyrosine phosphorylated (36-38), raising 
the possibility that loss of E-cadherin could impair p120 function. We found that E-
cadherin defective tumour cells exhibited a reduction in p120–catenin levels (Fig. 
6B), consistent with recent findings from a large-scale analysis of breast tumours 
with/without E-cadherin defects (39). Furthermore, as well as ROS1 
immunoprecipitating with p120 (Fig. 6C), we found that ROS1 inhibition: (i)  
exacerbated the p120 reduction seen in E-cadherin defective cells; (ii) reduced 
tyrosine phosphorylation of p120; and (iii) reduced p120 levels at the cleavage 
furrow (Fig. 6B-C; Supplementary Fig. S16A and B). We also found that siRNA-
mediated gene silencing of p120 (or ROS1) caused a multinuclear phenotype and 
elicited synthetic lethality in E-cadherin defective but not E-cadherin wild type cells 
(Fig. 6D-G). In normal epithelial cells, two opposing forces facilitate cytokinesis: (i) 
force provided by E-cadherin-dependent adherens junctions (AJ) at the apical 
membrane; and (ii) force provided by the contraction of the actomyosin ring at the 
cleavage furrow (40). One model to explain our observations might be that loss of 
one of these opposing forces in E-cadherin defective cells causes a greater 
reliance on processes and proteins that control cleavage furrow formation, such as 
p120 catenin. Our data suggest that ROS1 inhibitors exacerbate an existing p120 
defect in E-cadherin defective cells and impair cytokinesis to such an extent that 
abnormal mitoses form; this elicits a DNA damage response (e.g. induction of p21 
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and γH2AX) and ultimately apoptosis. ROS1 inhibition has lesser effects when 
buffered by the activity of wild type E-cadherin.  
 
Consistent with the concept that E-cadherin defects might cause a dependency 
upon processes controlled by actomyosin networks, such as cleavage furrow 
maturation, we also noted that the Rho GTPase effector kinase CDC42BPA 
(CDC42-binding kinase, MRCKα) which controls actomyosin function (41) was also 
identified as a robust synthetic lethal effect in our earlier siRNA screens 
(Supplementary Fig. S4A and B). We validated this synthetic lethal effect in 
subsequent experiments, including those using a toolbox small molecule MRCKα 
inhibitor (42) (Supplementary Fig. S17A-D), suggesting that additional targets 
associated with these processes might exist in E-cadherin defective cancers. 
 
ROS1/E-cadherin synthetic lethality operates in multiple in vivo models of 
breast cancer 
To assess the in vivo therapeutic potential of foretinib and crizotinib, we tested the 
ability of these drugs to affect the growth of E-cadherin defective invasive mammary 
carcinomas derived from the K14cre;Cdh1F/F;Trp53F/F (KEP) mouse ILC model; these 
mammary carcinomas show a strong resemblance to human ILC (43,44). E-cadherin 
defective mammary tumours from K14cre;Cdh1F/F;Trp53F/F (KEP) female mice were 
orthotopically transplanted into recipient mice and once established, animals were 
treated with foretinib, crizotinib or drug vehicle. In mice that received the drug vehicle 
alone, tumour growth continued unabated; in contrast, either foretinib or crizotinib 
treatment had a strong anti-tumour effect, reduced tumour volume and extended the 
survival of tumour-bearing mice (Fig. 7A-H, ANOVA p < 0.0001 in each case). 
Foretinib or crizotinib treatment also elicited a reduction in the proliferative index of 
tumours (as estimated by Ki67 immunohistochemistry) and an apoptotic response 
(Fig. 7D). The reduction in tumour volume in the early stages of crizotinib treatment is 
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highlighted in Fig. 7F. Similar studies in mice bearing MCF7A02 or MCF7Parental derived 
xenografts also established that the anti-tumour effect of foretinib was significantly 
enhanced by the absence of E-cadherin (Supplementary Fig. S18A-E). We also 
assessed the anti-tumour effect of foretinib treatment in an E-cadherin defective 
patient-derived breast tumour xenograft (PDX) model, BCM2665, which was derived 
from a female with ER-negative, HER2-negative, basal-like breast cancer (Fig. 7I) 
(45). As before, foretinib significantly inhibited the growth of established tumours (p < 
0.0001, ANOVA) and extended the survival of mice (Fig. 7J and K). E-cadherin 
defective tumours from mice treated with foretinib also consistently exhibited a 
profound reduction in levels of Ki67, suggesting a severe impairment in proliferative 
rate, showed increased levels of cleaved caspase-3, a marker of tumour cell 
apoptosis and had reduced hematoxylin and eosin staining, suggesting tumour 
necrosis (Fig. 7L). Given the availability of an immunohistochemical assay for 
measuring total and phosphorylated ROS1 in human tumours, we also established 
that foretinib treatment resulted in a decrease in pROS1 and total ROS1 
(Supplementary Fig. S19).  
 
Discussion  
E-cadherin defects are a common characteristic of human tumours. Here we show 
that ROS1 inhibition constitutes an E-cadherin synthetic lethal interaction that can be 
elicited with clinical inhibitors such as crizotinib or foretinib. These effects appear to 
be robust in the face of considerable molecular heterogeneity that exist between 
different isogenic models, distinct tumour cell lines, ex vivo breast tumour explants 
and two different mouse models of E-cadherin defective breast cancer. The profound 
anti-tumour effects seen in mice with E-cadherin defective tumours suggests that the 
observed synthetic lethal effect might also have translational utility. Several distinct 
approaches can be used to assess the potential of ROS1 inhibitors in E-cadherin 
defective cancers. For example, clinical trials in advanced forms of ILC, where E-
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cadherin defects are common, might seem appropriate. In such trials, absence of E-
cadherin using immunohistochemical analysis could be used to pre-select 
appropriate patients for treatment. As crizotinib is already used in the treatment of 
non-small cell lung cancer, and has been the subject of prior clinical safety 
assessment, this drug seems a reasonable candidate for testing in such trials.  
 
Mechanistically, our data suggests that loss of E-cadherin imparts upon cells a 
dependency upon ROS1 that is likely related to the ability to undergo cytokinesis. 
Our work suggests that p120 defects could play a role in these phenotypes, but it 
also seems possible that other proteins contribute to the synthetic lethal phenotype. 
For example, we also found that other proteins associated with actomyosin control 
such as MRCKα are also synthetic lethal with E-cadherin defects; these could 
conceivably play a part in the ROS1/E-cadherin synthetic lethal effect. Whilst drug-
like inhibitors of Rho effector kinases such as MRCKα are still in development (46), 
licenced drugs such as crizotinib, might provide an actionable approach to targeting 
E-cadherin defective cancers. Similarly, although we were able to elicit E-cadherin 
synthetic lethal effects with multiple different ROS1 siRNA reagents and to partially 
reverse crizotinib sensitivity with a p.G2032R mutant ROS1 fusion cDNA (Fig. 2), the 
anti-tumour therapeutic effect of drugs such as crizotinib or foretinib could also be 
influenced by inhibition of kinases other than ROS1. Although we were unable to 
elicit synthetic lethality with siRNAs for MET, ALK, AXL and KDR in isogenic or non-
isogenic systems (Supplementary Fig. S2 and S5), we cannot formally exclude the 
possibility that other kinase targets of foretinib or crizotinib also contribute to the E-
cadherin synthetic lethality. It seems possible that clinical studies where mechanisms 
of resistance to crizotinib in E-cadherin defective tumours are assessed will inform 
this area. 
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Materials and Methods  
Materials and cell lines 
Small-molecule inhibitors were obtained from SelleckChem. siRNAs were obtained 
from GE Dharmacon. Cell lines were obtained from American Type Culture 
Collection (ATCC) and European Collection of Cell Cultures (ECACC) in 2010-2011 
and maintained according to the supplier’s instructions as described in (19,47). The 
MCF10A CDH1-/- and MCF10A CDH1+/+ isogenic cell lines, were obtained in 2014 
from Sigma Aldrich, and maintained according to the supplier’s instructions. At sixth-
monthly intervals and prior to storage, the identity of each cell line was confirmed by 
short tandem repeat (STR) profiling of 10 loci using the GenePrint 10 system 
(Promega). At monthly intervals, mycoplasma testing of cell cultures was carried out 
using MycoAlert Mycoplasma Detection Kit (Lonza). 
 
CRISPR-Cas9 targeting  
MCF7 cells were targeted using the Edit-R-CRISPR-CAS9-gene engineering kit (GE 
Dharmacon) according to the supplier’s instructions. The following crRNA sequence 
was used: 5’GCUGAGGAUGGUGUAAGCGAGUUUUAGAGCUAUGCUGUUUUG 3’. 
MCF7 cells were transfected in 24 well plates (100,000 cells/well) with tracerRNA, 
crRNA and Cas9 plasmid. 72 hours after transfection, cells were plated in 15 cm 
dishes and continuously cultured until colonies formed. Colonies were recovered and 
profiled using PCR and Sanger sequencing to determine the presence of CDH1 
mutations.  
 
RNAi and small-molecule synthetic lethal screens  
siRNA screens and small-molecule screens were performed as described in (19,48). 
See also Supplementary Materials and Methods for details. 
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Cell survival and apoptosis assays 
Cell survival analysis was conducted as previously describes (49).  See also 
Supplementary Materials and Methods for details. 
 
Protein analysis 
Whole-cell protein extracts were prepared from cells lysed in NP250 buffer (20 mM 
Tris pH 7.6, 1 mM EDTA, 0.5 % NP40, 250 mM NaCl); supplemented with protease 
inhibitor cocktail tablets (Roche, Burgess Hill, UK). Protein concentrations were 
measured using BioRad Protein Assay Reagent (BioRad, Hemel Hempstead, UK). 
For Western blot analysis, 50 g of whole cell lysates were electrophoresed on 
Novex 4–12% gradient bistris pre-cast gels (Invitrogen) and immunoblotted overnight 
at 4C with antibodies listed in Supplementary Table S11. 
 
Confocal microscopy 
Cells were plated on coverslips and exposed to drugs the following day. After drug 
exposure, cells were fixed in 4% (v/v) paraformaldehyde for 10 minutes, washed, 
permeabilized in 0.2% (v/v) Triton X-100 in PBS for 20 minutes, washed, and blocked 
in IFF (1% (w/v) bovine serum albumin, 2% (v/v) FBS in PBS) then immunostained 
with primary antibodies targeting F-Actin conjugated to Alexa Fluor 488 and Tubulin 
(Santa Cruz Biotech) and detected with a Texas red conjugated secondary antibody 
(Supplementary Table S11). DAPI staining was used to detect nuclei. Mitotic and 
nuclear phenotypes of at least 200 cells per condition were scored in each replicate 
experiment. Confocal experiments were imaged using Zeiss CLM700. 
 
Time lapse microscopy 
Time-lapse microscopy was performed in 6 well plates using a Diaphot inverted 
microscope (Nikon), in a humidified CO2 chamber at 37°C, using a motorized stage 
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(Prior Scientific), controlled by Simple PCI software (Compix). Cells were first 
transfected with a mCherry-H2B plasmid, FACS sorted for mCherry-H2B to facilitate 
DNA visualization, and then exposed to foretinib or crizotinib for a 24 hour period, 
over which they were microscopically imaged. Sorting of cells is described in 
Supplementary Materials and Methods. 
 
Cell cycle analysis 
Measurements took place on a BD LSR II SORP flow cytometer (BD Biosciences, 
USA) equipped with a 488 nm blue laser, a 561 nm yellow laser, a 633 nm red laser 
and a 404 nm violet laser. Propidium Iodide was measured with 600 LP 610/20 BP. 
Cell population was gated in a FSC/SSC dot plot and doublets were gated out based 
on a DNA dye area/width dot plot. This cell population was further analyzed 
regarding its cell distribution (G1, S and G2/M phase) using Flow Jo V software.  
 
In vivo assessment of foretinib and crizotinib efficacy 
In vivo efficacy studies were conducted using K14cre;Cdh1F/F;Trp53F/F (KEP) or 
BCM2665 PDX tumour bearing mice as previously described (45,50). Experiments 
on K14cre;Cdh1F/F;Trp53F/F (KEP) tumour bearing mice were carried out at the 
Netherlands Cancer Institute according to local and international regulations and 
ethical guidelines, and were approved by the local animal experimental committee at 
the Netherlands Cancer Institute (DEC-NKI AvD:30100 2015 407 appendix 1, WP 
5791 and WP 5900). Balb/c nudes were implanted with K14cre;Cdh1F/F;Trp53F/F 
(KEP) tumour sections in their 4th mammary gland on the right side as described 
previously (50). Once tumours reached 200 mm3 in volume, mice were randomized 
into cohorts who received either crizotinib/foretinib 25mg/kg or 50mg/kg a day via 
oral gavage for 28 days or the drug vehicle. Operators were blinded to which cohort 
received foretinib or crizotinib and which received vehicle. A surrogate of animal 
survival was used and defined by the amount of time taken for tumours to reach a 
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pre-agreed volume of 1500mm3, at which point mice were sacrificed. Experiments 
using the BCM 2665 PDX model were conducted at the ICR according to local (UK 
Home Office) and international regulations and ethical guidelines, and were approved 
by the local animal experimental committee at the Institute of Cancer Research. 
Viably frozen fragments of the BCM2665 model (45) were obtained from Dr. Michael 
Lewis, Baylor College of Medicine, USA, under material transfer agreement and 
propagated in SCID-Beige and NSG hosts. SCID-beige host mice were obtained 
from Charles River at 21-28 day of age and were implanted with BCM2665 tumour 
fragments (~2mm in length) subcutaneously into the inguinal mammary fat pad 
following standard procedures. Once tumours measured 2 mm in diameter (assessed 
by palpation and caliper measurement), mice were randomized into cohorts who 
received either foretinib (25mg/kg) or the drug vehicle (1% 
hydroxypropylmethylcellulose, 0.2% SDS in H2O) every other day (4 days per week) 
by oral gavage. Operators were blinded to which cohort received foretinib and which 
received vehicle. Tumour growth was monitored over time (assessed by palpation 
and caliper measurement) and a surrogate of animal survival defined by the amount 
of time taken for tumours to reach a pre-agreed 12mm diameter, at which point mice 
were sacrificed and tumours excised. Tumour volume was calculated using the 
formula: V= ( x length x width2/6), where the length is the largest tumour diameter 
and width is the perpendicular diameter. Statistical analysis was performed using 
Prism. Tumours were formalin-fixed paraffin-embedded and slides were stained with 
H&E, or immunohistochemistry with antibodies against Ki-67 and cleaved caspase-3 
was undertaken using standard procedures.  
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Figure 1. ROS1 inhibition is synthetic lethal with E-cadherin defects in isogenic 
models. A, Wild-type E-cadherin protein is lost in the CDH1 CRISPR-Cas9 
mutagenised MCF7A02 clone. Western blot illustrating E-cadherin expression in 
parental MCF7 cells (MCF7parental) and the MCF7A02 clone is shown. Upper band is a 
glycosylated isoform of E-cadherin, the lower band representing the non-glycosylated 
form. B, Confocal microscopy images of MCF7parental and MCF7A02 cells, illustrating 
loss of E-cadherin expression (green) in MCF7A02 cells. Nuclei are imaged with DAPI 
(blue). C, Light microscopy images of MCF7parental and MCF7A02 cells, illustrating 
reduction in cell-cell contact in MCF7A02 cells. D, Volcano plot illustrating AUC ratios 
(MCF7A02 E-cadherin defective/MCF7 E-cadherin wild type parental cells) of 80 small 
molecule inhibitors assessed in the high-throughput screen. AUC ratio <1 indicates 
candidate E-cadherin synthetic lethal effects. Blue dots represent ROS1 inhibitors. E, 
Volcano plot of data from the siRNA SMARTpool sensitivity screens in cell lines 
described in (B). Blue dot highlights ROS1 siRNA identified in the screen as 
selectively targeting E-cadherin defective cells. F, ROS1 expression is upregulated in 
E-cadherin defective cells. Western blot showing expression of ROS1, MET and ALK 
in MCF10A CDH1+/+ and MCF10A CDH1–/– cells. ACTIN expression is used as 
loading control. G, Illustrative confocal microscopy images indicating an increase in 
ROS1 expression in E-cadherin defective MCF10A CDH1–/– cells compared to 
MCF10A CDH1+/+ cells. ROS1 expression is shown in red, E-cadherin in green and 
DNA in blue. H, Ectopic expression of E-cadherin in MCF7A02 E-cadherin defective 
cells reduces ROS1 expression. Western blot illustrating ROS1 expression in E-
cadherin defective MCF7A02 cells transfected with FLAG epitope-CDH1 cDNA. 
ACTIN is used as loading control. 
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Figure 2. Validation of ROS1 synthetic lethality in E-cadherin defective isogenic 
models. A, Western blot illustrating ROS1 silencing caused by four different ROS1 
siRNAs (1, 2, 3 and 4) compared to two different non-targeting siRNAs (siCONT1, 
siCONT2). Uncropped western blot images are shown in Supplementary Fig. S20. B, 
and C, Bar charts illustrating cell inhibition caused by ROS1 siRNAs in MCF7parental 
and MCF7A02 cells (B) and MCF10A CDH1+/+ and MCF10A CDH1–/– cells (C). NPI = 
normalized percentage inhibition (compared to siCONT (NPI=1) and siPLK1 
(NPI=0)). Error bars represent standard error of the mean (SEM) from three 
independent experiments. D, Bar chart illustrating the effect of 1 µM foretinib or 
crizotinib in MCF7parental compared to two additional E-cadherin defective clones, 
MCF7B04 and MCF7B05. Error bars represent SEM from three independent 
experiments. E, Western blot illustrating E-cadherin expression in MCF7A02 cell line 
model transfected with a FLAG epitope-CDH1 cDNA expression construct. F, 
Surviving fraction data from MCF7A02, MCF7parental and MCF7A02 +FLAG-CDH1 cell lines 
exposed to 1µM foretinib, crizotinib and TAE684. Cells were transfected with FLAG 
epitope-CDH1 cDNA and clones selected in G418. Clones expressing FLAG epitope-
E-cadherin were exposed to 1 µM foretinib, crizotinib or TAE684 for six continuous 
days, at which point cell viability was assessed. *p<0.05 Student’s t-test as shown. 
G, Dot chart illustrating cell survival effects of ROS1/MET/ALK inhibitors in 
MCF7parental and MCF7A02 cells. SF50 = surviving fraction 50 (concentration required to 
cause 50 % reduction in survival). H, and I, Dose-response survival curves in 
MCF10A CDH1+/+ and MCF10A CDH1–/– cells exposed to foretinib for six days (H) or 
two weeks (I). Error bars represent SEM from three independent experiments. In 
each case, ANOVA p value MCF10A CDH1+/+ vs. MCF10A CDH1–/– cells < 0.0001. 
Dose-response in SLC34A2-ROS1 translocation-positive HCC78 cells is shown as a 
positive control. J, Dose-response survival curves in MCF10A CDH1+/+ and MCF10A 
CDH1–/– cells exposed to ROS1 kinase inhibitor PF-06463922 for six days. Error bars 
represent SEM from three independent experiments. K, Dose-response survival 
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curves in MCF7A02 cells transfected with different concentrations of ROS1 siRNA 
SMARTpool and subsequently exposed to foretinib for six days. Increasing 
concentration of ROS1 siRNA caused a dose-dependent reduction in foretinib SF50. 
Error bars represent SEM from three independent experiments. L, Expression of a 
crizotinib-refractory p.G2032R mutant ROS1 fusion cDNA (18) causes crizotinib 
resistance in E-cadherin defective MCF10A CDH1-/- cells. Cells were transfected 
with either a p.G2032R CD74-ROS1 cDNA expression vector or a cDNA expression 
vector without a CD74-ROS1 insert (“empty”). Twenty-four hours after transfection, 
cells were exposed to crizotinib for a subsequent six days, at which point cell viability 
was assessed. Data shows the median effects of three independent experiments. 
Error bars illustrate the SEM. ***p < 0.001 Student’s t test as shown. 
 
Figure 3. Synthetic lethality of ROS1 inhibition in E-cadherin deficient breast 
tumour cell lines. A, Western blot illustrating E-cadherin expression in 37 breast 
tumour cell lines (including MCF7 as positive control). Cell line names are colour-
coded according to the presence of CDH1 gene mutations, gene deletion events or 
CDH1 promoter hypermethylation events. Uncropped western blot images are shown 
in Supplementary Fig. S20. B, Schematic illustrating breast tumour cell line cohort 
sizes used to interrogate siRNA sensitivity screens (19). C, Bar chart illustrating E-
cadherin expression of a subset of the breast tumour cell lines shown in (A), 
determined by mass spectrometry, described in (20). Western blot classification of E-
cadherin status from (A) is shown. D, Scatter plot illustrating CDH1 mRNA 
expression levels in breast tumour cell lines from the CCLE dataset (51). E, Volcano 
plot of data from the siRNA SMARTpool sensitivity screens described in (B). Blue dot 
highlights ROS1 siRNA identified in the screen as selectively targeting E-cadherin 
defective cells. F, REVEALER analysis identifies E-cadherin status as an important 
determinant of ROS1 siRNA sensitivity. Heatmap illustrates the REVEALER output 
identifying complementary genomic alterations associated with ROS1 siRNA 
E-cadherin synthetic lethality in breast cancer                                                                                                                 31 
sensitivity in the 34 breast tumour cell line panel described in (B). IC (information 
correlation coefficient) scores and nominal p values with respect to the target are 
shown on the right side of the heatmap. E-cadherin status demonstrated the most 
profound IC score -0.5 from 23 molecular features examined. G, and H, Box whisker 
plots illustrating foretinib (G) or crizotinib (H) sensitivity in 12 breast tumour cell lines, 
defined by log2 area under the curve (AUC) values. Individual AUC values are listed 
in Supplementary Table S8. Log2 AUC values for SLC34A2-ROS1 translocation-
positive HCC78 cells are shown as a positive control. ** p value = 0.003, Student’s t-
test, * p value =0.035 Student’s t-test. I, Volcano plot of drug sensitivity effects in ex 
vivo cultured breast cancer explants (27) annotated according to CDH1 gene copy 
number. Red dot highlights crizotinib as selectively targeting explants with CDH1 
gene copy number loss. Median AUC in explants with CDH1 copy number loss = 
0.0713, median AUC in explants without CDH1 copy number loss = 0.138, p value 
=0.00127. Y-axis shows adjusted p-value (-log10) from a t-test comparing AUC in ex 
vivo explant models with CDH1 loss vs. models with no CDH1 copy number change. 
X-axis shows the negative value of the t-statistic describing the difference in AUC 
means for ex vivo explant models with CDH1 loss vs. models with no CDH1 copy 
number change. Negative values suggest drug sensitivity in ex vivo explant models 
with CDH1 loss vs. models with no CDH1 copy number change. 
 
Figure 4. E-cadherin/ROS1 synthetic lethality is independent of endocrine 
therapy resistance. A, Dose-response survival curves in MCF7 and MCF7 LTED 
cells exposed to fulvestrant for five days. Error bars represent SEM from three 
independent experiments. B, and C, Dose-response survival curves in MCF7 LTED 
cells transfected with two independent E-cadherin (CDH1) siRNA reagents; siRNA 1 
(B) and siRNA 2 (C) and a non-targeting siRNA (siCONT1) for 48 hours and 
subsequently exposed to foretinib or fulvestrant for five days. Error bars represent 
SEM from three independent experiments. ANOVA p value MCF7 LTED transfected 
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with two independent E-cadherin siRNA reagents vs. MCF7 LTED transfected with 
siCONT1 cells p < 0.0001 for foretinib. No statistically significant difference was 
observed in the same cells exposed to fulvestrant. D, and E, Dose-response survival 
curves in cells as in (B) and (C) exposed to crizotinib or fulvestrant for five days. 
Error bars represent SEM from three independent experiments. ANOVA p value 
MCF7 LTED transfected with two independent E-cadherin siRNA reagents vs. MCF7 
LTED transfected with siCONT1 cells p < 0.0001 for crizotinib. No statistically 
significant difference was observed in the same cells exposed to fulvestrant. 
 
Figure 5. Cell cycle and mitotic defects in E-cadherin defective cells. A, FACS 
plots illustrating increase in DNA content in E-cadherin defective MCF7A02 cells 
exposed to foretinib. B, Enlarged image from (A) indicating >4n fraction. The fraction 
of cells with >4n DNA content is shown. C, Box whisker plots indicating fraction of 
cells with abnormal mitoses (e.g. multinuclear defects) in cells exposed to foretinib. 
*** p value = 0.0001, ** p value = 0.0054, Student’s t-test. Nuclear defects were 
visualized by confocal microscopy and a minimum of 200 cells were counted for each 
cell line. Data is representative of two independent experiments in each case. D, 
Illustrative confocal microscopy images indicating multinuclear phenotype in E-
cadherin defective MCF7A02 cells exposed to foretinib. E, Illustrative confocal 
microscopy images indicating multinuclear phenotype in E-cadherin defective SKBR3 
and BT549 cells and E-cadherin wild-type T47D and SUM149 cells exposed to 1μM 
foretinib. F, Box whisker plots indicating fraction of cells with abnormal mitoses (e.g. 
multinuclear defects) in cells exposed to foretinib. * p-value =0.021, Student’s t-test. 
Data is representative of two independent experiments in each case. G, Western blot 
illustrating increased p21 levels in the E-cadherin defective MCF7A02 cells exposed to 
1µM foretinib vs. MCF7parental cells. H, Bar chart illustrating increased caspase 3/7 
activity in E-cadherin defective cells exposed to either crizotinib or foretinib. Median 
effects from three independent experiments are shown, with error bars representing 
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the SEM. I, Bar chart illustrating increased caspase 3/7 activity in E-cadherin 
defective cells transfected with a siRNA targeting ROS1. siPLK1 was used as a 
positive control. p<0.05 between E-cadherin defective vs. wild-type groups, using the 
Student’s t-test. Median effects from three independent experiments are shown, with 
error bars representing the SEM. Bar chart illustrating increased caspase 3/7 activity 
in E-cadherin defective MCF7A02 J BT549 K and SKBR3 L cells exposed to either 
crizotinib or foretinib, compared to E-cadherin wild type MCF7Parental cells. * p < 0.01, 
** p < 0.001 and *** p < 0.0001, E-cadherin defective vs. MCF7Parental cells, Student’s 
t-test. Median effects from three independent experiments are shown, with error bars 
representing the SEM.  
 
Figure 6. ROS1 inhibition exacerbates p120 catenin and cytokinesis defects in 
E-cadherin defective cells (previous page). A, Time lapse microscopy images 
illustrating cell division in MCF7Parental (top panel) and E-cadherin defective MCF7A02 
(bottom panel) cells exposed to foretinib, crizotinib or vehicle. MCF7A02 and 
MCF7Parental cells were first transfected with a mCherry-H2B plasmid, FACS sorted for 
mCherry-H2B to facilitate DNA visualization, and then exposed to foretinib, crizotinib 
or vehicle for a 24-hour period. Initial formation of the cleavage furrow, followed by 
formation of a multinuclear cell is highlighted with white arrows. Scale bar, 10 μm. B, 
Loss of E-cadherin is associated with a reduction in p120 levels and ROS1 inhibition 
causes a reduction in p120 tyrosine phosphorylation. Western blot showing phospho-
p120 (Tyr228) and total p120 catenin levels in MCF10A CDH1+/+ and MCF10A 
CDH1–/– cells, exposed to a range of foretinib concentrations (vehicle, 0.03 µM, 0.1 
µM, 0.3 µM or 1 µM) for 16 hours. C, ROS1 interacts with p120. Western blot 
illustrating co-immunoprecipitation of GFP-p120 and FLAG-ROS1 proteins in 
MCF7A02 cells. D, Western blot illustrating p120 catenin silencing caused by two 
different p120 siRNAs (sip120_1 and _2) compared to a non-targeting siRNA 
(siCONT1). E, p120 or ROS1 siRNA causes mitotic defects in E-cadherin defective 
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cells. Bar chart indicating fraction of cells with abnormal mitoses in cells transfected 
with siRNAs targeting p120 or ROS1 siRNAs. *** p value < 0.0001, ** p value < 
0.001, Student’s t-test. A minimum of 100 cells were analyzed for each cell line. Data 
is representative of three replica experiments, error bars represent SEM. F, p120 
gene silencing is synthetically lethal with E-cadherin deficiency. Bar chart illustrating 
cell inhibition caused by two different p120 siRNAs (1 and 2) in E-cadherin wild type 
MCF7Parental and E-cadherin defective MCF7A02 cells. NPI = normalized percentage 
inhibition (compared to non-targeting siRNA, siCONT (NPI=1) and cytotoxic siRNA 
targeting PLK1 (NPI=0)). Error bars represent standard error of the mean (SEM) from 
three independent experiments. *** p value < 0.0001, Student’s t-test. G, 
Representative images from a colony forming assay illustrating cell inhibition caused 
by two different p120 siRNAs (1 and 2) or ROS1 siRNA in E-cadherin wild type 
MCF7Parental and E-cadherin defective MCF7A02 cells. A non-targeting siRNA, siCONT 
and siPLK1 are used as controls. 
 
Figure 7. E-cadherin synthetic lethal effects operate in vivo in E-cadherin 
defective breast tumours. A, Therapeutic response to foretinib treatment in mice 
bearing E-cadherin deficient mammary tumours. Mammary tumour fragments from 
KEP mice were transplanted into 22 recipient mice; once tumours had established, 
animals were treated over a 27-day period with either drug vehicle or foretinib (25 or 
50 mg/kg every other day, n=8 for vehicle-treated cohorts and n=7 for each drug 
treatment cohort). Tumour volumes after the initiation of treatment are shown. 
ANOVA p<0.0001 for both foretinib treatment regimes compared to vehicle-treated 
mice. B, Kaplan–Meier plot of data from (A) indicating anti-tumour efficacy of 25 
mg/kg foretinib treatment. Mice were sacrificed once tumours reached a volume of 
1500 mm3. C, Kaplan–Meier plot of data from (A) for vehicle vs. foretinib 50 mg/kg 
cohort. D, Immunohistochemistry images of tumours extracted from animals from (A) 
at the end of foretinib treatment are shown. Representative images of H&E, Ki67 and 
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cleaved Caspase 3 are shown (magnification = 20x). Scale bar represents 250µm. E, 
Therapeutic response to crizotinib treatment in mice bearing KEP tumour allografts 
as in (A). ANOVA p<0.0001 for both crizotinib treatment regimes compared to 
vehicle-treated mice. F, Data from (E), plotted to illustrate tumour volume reduction in 
both crizotinib treated cohorts. G, Kaplan–Meier plot of data from (E), indicating 
effect of 25 mg/kg crizotinib treatment. H, Kaplan–Meier plot of data from (E) for 
vehicle vs. crizotinib 50 mg/kg cohort. I, Immunohistochemistry images illustrating 
lack of E-cadherin expression in a patient-derived xenograft (PDX) model of breast 
cancer (BCM2665) compared to positive (HCC1954 breast tumour cells) and 
negative controls (MDAMB231 breast tumour cells). J, Therapeutic response to 
foretinib treatment in mice bearing BCM2665 PDX. BCM2665 was transplanted into 
19 recipient mice; once tumours had established, animals were treated over a 47-day 
period with either drug vehicle (n=11), or foretinib (25 mg/kg every other day, n= 8) 
as shown. ANOVA = p<0.0001. K, Kaplan–Meier plot of data from (I). L, 
Representative images of FFPE tumours from animals in (I) stained with H&E, Ki67 
and cleaved caspase 3 are shown (magnification = 20x). Scale bar represents 
250µm. 
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